Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 18.9% in October

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 34,300 shares, a drop of 18.9% from the September 30th total of 42,300 shares. Based on an average trading volume of 95,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company’s stock are sold short.

Talphera Price Performance

Shares of Talphera stock opened at $0.96 on Wednesday. The firm has a market cap of $16.31 million, a price-to-earnings ratio of -1.08 and a beta of 0.32. Talphera has a 52-week low of $0.43 and a 52-week high of $1.61. The stock has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $0.95.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, equities research analysts predict that Talphera will post -0.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Talphera in a research report on Friday, August 16th.

Institutional Investors Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC purchased a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera at the end of the most recent reporting period. Institutional investors and hedge funds own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.